IBD in 2011: Advances in IBD managementg-towards a tailored approach

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 2, 2012, Pages 70-72

  De Chambrun, Guillaume P Pineton ^a   Sandborn, William J ^b  

^a UNIVERSITÉ DE LILLE   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIMETABOLITE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; HUMAN; LYMPHOPROLIFERATIVE DISEASE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; RETREATMENT; REVIEW; RISK FACTOR; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856969702     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.248     Document Type: Review

References (10)

1. Barrett, J. C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955-962 (2008).
2. Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462-2476 (2005). (Pubitemid 41770166)
3. Reinisch, W. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60, 780-787 (2011).
4. Pineton de Chambrun, G., Peyrin-Biroulet, L., Lemann, M. & Colombel, J. F. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. 7, 15-29 (2010).
5. Colombel, J. F. et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141, 1194-1201 (2011).
6. Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010).
7. Van Assche, G. et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut http:// dx.doi.org/gutjnl-2011-300755.
8. Louis, E. et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology http://dx/ doi.org/10.1053/j.gastro.2011.09.034.
9. Beaugerie, L. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374, 1617-1625 (2009).
10. Coelho, J. et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 60, 198-203 (2011).